Clinical Trial Update: An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating cenegermin ophthalmic solution versus vehicle for persistent corneal epithelial defect, with the study status listed as n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Persistent Corneal Epithelial Defect

Drugs mentioned

• Oxervate (cenegermin)

Snippet

Sponsor: Dompé Farmaceutici S.p.A | Conditions: Persistent Corneal Epithelial Defect | Phase 3 | Status: NOT_YET_RECRUITING